clinical trial · NCT05116891
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Advanced Solid TumorsColorectal CancerNon Small Cell Lung CancerBiliary Tract CancerCAN04 (nadunolimab)mFOLFOXDTXG/C
brief summary
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).
started
Sep 22, 2021
primary completion
Jun 23, 2023
completion
Jun 23, 2023
last updated
Jul 3, 2023
official title
A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol